{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T18:54:24Z","timestamp":1767898464400,"version":"3.49.0"},"reference-count":46,"publisher":"Impact Journals, LLC","issue":"35","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,8,30]]},"DOI":"10.18632\/oncotarget.11012","type":"journal-article","created":{"date-parts":[[2016,8,2]],"date-time":"2016-08-02T14:47:56Z","timestamp":1470149276000},"page":"57145-57159","source":"Crossref","is-referenced-by-count":6,"title":["Analysis of the chemotherapeutic effects of a propadiene compound on malignant ovarian cancer cells"],"prefix":"10.18632","volume":"7","author":[{"given":"Shuqing","family":"Li","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, The Fifth People's Hospital of Shanghai, Fudan University, Shanghai 200240, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, The Fifth People's Hospital of Shanghai, Fudan University, Shanghai 200240, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingshu","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, The Fifth People's Hospital of Shanghai, Fudan University, Shanghai 200240, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, The Fifth People's Hospital of Shanghai, Fudan University, Shanghai 200240, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Pathology, Fudan University Shanghai Cancer Center, and Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huafen","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, The Fifth People's Hospital of Shanghai, Fudan University, Shanghai 200240, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Honglin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, The Fifth People's Hospital of Shanghai, Fudan University, Shanghai 200240, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gong","family":"Yang","sequence":"additional","affiliation":[{"name":"Cancer Institute, Fudan University Shanghai Cancer Center, and Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China"},{"name":"Central laboratory, The Fifth People's Hospital of Shanghai, Fudan University, Shanghai 200240, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaping","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, The Fifth People's Hospital of Shanghai, Fudan University, Shanghai 200240, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2016,8,2]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.canlet.2015.03.040","article-title":"Molecular characterization of 7 new established cell lines from high grade serous ovarian cancer","volume":"362","author":"Cacsire Castillo-Tong","year":"2015","journal-title":"CANCER LETT"},{"key":"2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.canlet.2015.09.006","article-title":"F14512, a polyamine-vectorized inhibitor of topoisomerase II, exhibits a marked anti-tumor activity in ovarian cancer","volume":"370","author":"Annereau","year":"2016","journal-title":"CANCER LETT"},{"key":"3","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/nrc4019","article-title":"Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer","volume":"15","author":"Martins","year":"2015","journal-title":"NAT REV CANCER"},{"key":"4","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/S0140-6736(13)62146-7","article-title":"Ovarian cancer","volume":"384","author":"Ledermann","year":"2014","journal-title":"LANCET"},{"key":"5","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.bbcan.2014.09.008","article-title":"Portrait of the PI3K\/AKT pathway in colorectal cancer","volume":"1855","author":"Lothe","year":"2015","journal-title":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"},{"key":"6","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1038\/onc.2011.6","article-title":"E-cadherin inhibits tumor cell growth by suppressing PI3K\/Akt signaling via b-catenin-Egr1-mediated PTEN expression","volume":"30","author":"PC","year":"2011","journal-title":"ONCOGENE"},{"key":"7","doi-asserted-by":"publisher","first-page":"25520","DOI":"10.18632\/oncotarget.4550","article-title":"The PI3K\/AKT\/mTOR pathway is a potential predictor of distinct invasive and migratory capacities in human ovarian cancer cell lines","volume":"6","author":"Shen","year":"2015","journal-title":"ONCOTARGET"},{"key":"8","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/nature04869","article-title":"Ras, PI(3)K and mTOR signalling controls tumour cell growth","volume":"441","author":"Cantley","year":"2006","journal-title":"NATURE"},{"key":"9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00210-014-1032-y","article-title":"The Akt inhibitor MK-2206 enhances the cytotoxicity of paclitaxel (Taxol) and cisplatin in ovarian cancer cells","volume":"388","author":"Hsu","year":"2015","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10","doi-asserted-by":"crossref","first-page":"5497","DOI":"10.1038\/onc.2008.245","article-title":"PI3K pathway alterations in cancer: variations on a theme","volume":"27","author":"Cantley","year":"2008","journal-title":"ONCOGENE"},{"key":"11","doi-asserted-by":"crossref","first-page":"8782","DOI":"10.1158\/0008-5472.CAN-10-1352","article-title":"BRCA1-IRIS Overexpression Promotes Cisplatin Resistance in Ovarian Cancer Cells","volume":"70","author":"ElShamy","year":"2010","journal-title":"CANCER RES"},{"key":"12","doi-asserted-by":"crossref","first-page":"e1836","DOI":"10.1038\/cddis.2015.208","article-title":"ARHI (DIRAS3)-mediated autophagy-associated cell death enhances chemosensitivity to cisplatin in ovarian cancer cell lines and xenografts","volume":"6","author":"Lu","year":"2015","journal-title":"CELL DEATH DIS"},{"key":"13","doi-asserted-by":"crossref","first-page":"e1836","DOI":"10.1038\/cddis.2015.208","article-title":"ARHI (DIRAS3)-mediated autophagy-associated cell death enhances chemosensitivity to cisplatin in ovarian cancer cell lines and xenografts","volume":"6","author":"Lu","year":"2015","journal-title":"CELL DEATH DIS"},{"key":"14","article-title":"XIAP Regulates Akt Activity and Caspase-3-dependent Cleavage during Cisplatin-induced Apoptosis in Human Ovarian Epithelial Cancer Cells1","author":"Tsang","year":"2001","journal-title":"CANCER RES"},{"key":"15","first-page":"e142157","article-title":"Anti-Tumor Effect of Pinus massoniana Bark Proanthocyanidins on Ovarian Cancer through Induction of Cell Apoptosis and Inhibition of Cell Migration","volume":"10","author":"Li","year":"2015","journal-title":"PLOS ONE"},{"key":"16","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1517\/14728222.2011.639361","article-title":"The RAS\/RAF\/MEK\/ERK and the PI3K\/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches","volume":"16","author":"Normanno","year":"2012","journal-title":"Expert Opin Ther Targets"},{"key":"17","doi-asserted-by":"crossref","first-page":"883","DOI":"10.2174\/138161213804547187","article-title":"Modulation of Sensitivity to Antitumor Agents by Targeting the MAPK Survival Pathway","volume":"19","author":"Perego","year":"2013","journal-title":"CURR PHARM DESIGN"},{"key":"18","doi-asserted-by":"crossref","first-page":"4667","DOI":"10.1182\/blood-2002-12-3647","article-title":"Map kinase signaling pathways and hematologic malignancies","volume":"101","author":"Platanias","year":"2003","journal-title":"BLOOD"},{"key":"19","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1093\/emboj\/16.10.2634","article-title":"Activation of the JNK pathway is essential for transformation by the Met oncogene","volume":"16","author":"Schlessinger","year":"1997","journal-title":"EMBO J"},{"key":"20","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0145-2126(01)00099-6","article-title":"c-Jun N-terminal kinase\/stress-activated protein kinase (JNK\/SAPK) is required for mitoxantrone- and anisomycin-induced apoptosis in HL-60 cells","volume":"26","author":"Kucera","year":"2002","journal-title":"Leuk Res"},{"key":"21","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1038\/sj.onc.1207556","article-title":"Mitogen-activated protein kinases in apoptosis regulation","volume":"23","author":"Penninger","year":"2004","journal-title":"ONCOGENE"},{"key":"22","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.cellsig.2007.10.015","article-title":"Taxol-induced mitochondrial stress in melanoma cells is mediated by activation of c-Jun N-terminal kinase (JNK) and p38 pathways via uncoupling protein 2","volume":"20","author":"Hengge","year":"2008","journal-title":"CELL SIGNAL"},{"key":"23","article-title":"Chk1 and Chk2 kinases in checkpoint control and cancer","author":"Lukas","year":"2003","journal-title":"CANCER CELL"},{"key":"24","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1007\/s11095-014-1346-y","article-title":"Delivery of a Monomeric p53 Subdomain with Mitochondrial Targeting Signals from Pro-Apoptotic Bak or Bax","volume":"31","author":"Lim","year":"2014","journal-title":"PHARM RES-DORDR"},{"key":"25","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1128\/MCB.24.5.1823-1835.2004","article-title":"ATM and the catalytic subunit of DNA-dependent protein kinase activate NF-kappaB through a common MEK\/extracellular signal-regulated kinase\/p90(rsk) signaling pathway in response to distinct forms of DNA damage","volume":"24","author":"Arsura","year":"2004","journal-title":"MOL CELL BIOL"},{"key":"26","doi-asserted-by":"crossref","first-page":"e1257","DOI":"10.1038\/cddis.2013.428","article-title":"Systems biology of cisplatin resistance: past, present and future","volume":"5","author":"Kroemer","year":"2014","journal-title":"Cell Death and Disease"},{"key":"27","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.bbamcr.2014.01.019","article-title":"Aurora-A controls cancer cell radio- and chemoresistance via ATM\/Chk2-mediated DNA repair networks","volume":"1843","author":"Yang","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"28","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/mc.22205","article-title":"Akt confers cisplatin chemoresistance in human gynecological carcinoma cells by modulating PPM1D stability","volume":"54","author":"Tsang","year":"2015","journal-title":"MOL CARCINOGEN"},{"key":"29","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.molonc.2012.07.001","article-title":"Inhibition of doxorubicin-induced HER3-PI3K-AKT signalling enhances apoptosis of ovarian cancer cells","volume":"6","author":"Ullrich","year":"2012","journal-title":"MOL ONCOL"},{"key":"30","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/ijc.23086","article-title":"Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function","volume":"122","author":"Tsang","year":"2008","journal-title":"INT J CANCER"},{"key":"31","first-page":"14","article-title":"miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway","author":"Wiemer","year":"2015","journal-title":"MOL CANCER"},{"key":"32","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1038\/sj.onc.1210421","article-title":"MAP kinase signalling pathways in cancer","volume":"26","author":"Kolch","year":"2007","journal-title":"ONCOGENE"},{"key":"33","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/S0140-6736(09)61338-6","article-title":"ovarian cancer","volume":"374","author":"M","year":"2009","journal-title":"LANCET"},{"key":"34","first-page":"3253","article-title":"Differential induction of c-Jun NH2-terminal kinase and c-Abl kinase in DNA mismatch repair-proficient and -deficient cells exposed to cisplatin","volume":"57","author":"Christen","year":"1997","journal-title":"CANCER RES"},{"key":"35","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1124\/mol.60.6.1153","article-title":"Identification of genes that mediate sensitivity to cisplatin","volume":"60","author":"Howell","year":"2001","journal-title":"MOL PHARMACOL"},{"key":"36","doi-asserted-by":"publisher","first-page":"944","DOI":"10.18632\/oncotarget.1458","article-title":"Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch1 signaling in ovarian cancer","volume":"5","author":"Chan","year":"2014","journal-title":"ONCOTARGET"},{"key":"37","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/S1470-2045(13)70391-7","article-title":"Controversy in treatment of advanced ovarian cancer","volume":"14","author":"Amadio","year":"2013","journal-title":"LANCET ONCOL"},{"key":"38","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.biocel.2015.02.001","article-title":"Differential activation of NF-\u03baB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells","volume":"61","author":"Ray","year":"2015","journal-title":"The International Journal of Biochemistry & Cell Biology"},{"key":"39","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nature14410","article-title":"Whole-genome characterization of chemoresistant ovarian cancer","volume":"521","author":"Quinn","year":"2015","journal-title":"NATURE"},{"key":"40","doi-asserted-by":"crossref","first-page":"4662","DOI":"10.1200\/JCO.2011.36.1352","article-title":"Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II\/III epithelial ovarian cancer","volume":"29","author":"Aghajanian","year":"2011","journal-title":"J CLIN ONCOL"},{"key":"41","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(02)09738-6","article-title":"Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial","volume":"360","author":"Bertelsen","year":"2002","journal-title":"LANCET"},{"key":"42","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.1200\/JCO.2004.08.080","article-title":"Quality of life in ovarian cancer patients: comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study","volume":"22","author":"Eisenhauer","year":"2004","journal-title":"J CLIN ONCOL"},{"key":"43","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1158\/0008-5472.CAN-03-3380","article-title":"A genetically defined model for human ovarian cancer","volume":"64","author":"Bast","year":"2004","journal-title":"CANCER RES"},{"key":"44","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1158\/1078-0432.CCR-10-3265","article-title":"The biphasic role of NF-kappaB in progression and chemoresistance of ovarian cancer","volume":"17","author":"Liu","year":"2011","journal-title":"CLIN CANCER RES"},{"key":"45","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0959-8049(00)00431-7","article-title":"Combination effect of adenovirus-mediated pro-apoptotic bax gene transfer with cisplatin or paclitaxel treatment in ovarian cancer cell lines","volume":"37","author":"Fujii","year":"2001","journal-title":"EUR J CANCER"},{"key":"46","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/978-1-61779-080-5_20","article-title":"Cell sensitivity assays: the MTT assay","volume":"731","author":"Cloos","year":"2011","journal-title":"Methods Mol Biol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.11012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T10:58:04Z","timestamp":1589281084000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.11012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,2]]},"references-count":46,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2016,8,30]]}},"alternative-id":["11012","27494891"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.11012","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,2]]}}}